Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Zebra 365 who wrote (2170)	11/7/1997 3:23:00 AM
From: Steve Childs	Respond to of 23519

Can't find my original source. This is what I could retrieve: "In a study of Pfizer's Viagra (abstract #793, "Sildenafil, an oral treatment for erectile dysfunction: a 1-year, open-label, extension study"), while use of Viagra resulted in a 60 percent intercourse rate, it should be noted that the 311 patients treated in this study had erectile dysfunction of NO KNOWN ORGANIC CAUSE, whereas nearly all of the 700+ patients enrolled in INVICORP's Phase III clinical trials suffered from moderate-to-severe, organic-based ED." This was from a release from Senetek on Invicorp. BTW: How can Pfizer be doing a marketing campaign (making public statements, etc.) about an unapproved drug? Also, have there been any studies by PFE on the effects of alcohol and sildenafil mixed together? I suspect the result would be disastrous. Invicorp, by the way, (provided that its autoinjector doesn't really hurt much), could get some business. It appears to be the most effective drug out there, at least from the trials. And finally, in looking at the charts (I'm not a TA, but I do look at charts), I don't see any solid floor for this stock, except at $15. What an incredible buying opportunity that would be! Hey Bond: you ignoring me? I was asking you what post # the Dain Bosworth notes you made is...thanks.